An active pharmaceutical ingredient (API) comprises or consists essentially of cannabidiol (CBD) and another cannabinoid (CB) selected from the group consisting of cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA) and tetrahydrocannabivarin (THCV) for use as a medicament, preferably for use in the treatment of cancer, is provided. The cancer is preferably selected from one or more of: breast cancer, liver cancer, lung cancer, pancreatic cancer, melanoma, ovarian cancer, gastric cancer, renal cancer or bladder cancer. In particular, the API combinations are: cannabidiol (CBD) and cannabigerol (CBG) and cannabidiol (CBD) and tetrahydrocannabivarin (THCV).
